Prof Piero Pollesello, PhD, FESC, FHFA
Cardiology — Orion Corporation (Group), Finland
Piero Pollesello
LeadR Profile
Cardiology
Subspecialties:
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Piero Pollesello has a PhD in medical biochemistry from the University of Trieste (Italy), and the title of Adjunct Professor in medical biochemistry at the University of Helsinki (Finland).
Active researcher and teacher from 1990, he has been Head of Cardiovascular Drug Discovery and Pharmacology at Orion Pharma (Finland), with substantial contribution to the discovery, patenting, development, registration and launch of a cardiovascular drug.
In his publication list there are over 150 peer-reviewed full papers (with h-index=58), and over 100 other scientific contributions (among which several book chapters and ten patents).
He has been an active member of the Translational Committee of the Heart Failure Association in two non consecutive terms, and co-authored many consensus papers. He has coordinated scientific communication strategies in cooperation with a broad network of international clinical experts in the ESC. He is currently Content & Communication Lead at Orion Pharma.
He has been a member of the Editorial Board of Journal of Cardiovascular Pharmacology for over 20 years and is editing and reviewing for other journals in the area. He is a fellow of both the European Society of Cardiology (FESC) and the Heart Failure Association (FHFA). He was created Knight of the Star of Italy in 2006 by the President of the Italian Republic, and Knight Officer of the Lion of Finland in 2011 by the President of the Finnish Republic for scientific merits.
Organizations
Career arc: 1992 - 2025
Number : 133
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Chronotropic Effects of Milrinone in a Guinea Pig Ex Vivo Model: A Pilot Study to Screen for New Mechanisms of Action. pilot projects, pilots, propranolol, heart rate, heart, cardiovascular agents, milrinone, receptors, serotonin, prazosin, metoprolol | J Cardiovasc Pharmacol | 2025 | 0 |
| Levosimendan as an Antidote in Experimental Calcium Channel Blocker Intoxication. verapamil, calcium channel blockers, poisoning, cardiovascular agents, calcium channels, calcium, diltiazem, antidotes, hemodynamics, survival rate | J Cardiovasc Pharmacol | 2024 | 0 |
| Repetitive Treatments With Inotropes in Advanced Heart Failure. heart failure, cardiovascular agents, therapeutics | J Cardiovasc Pharmacol | 2024 | 0 |
| The Catechol O-Methyltransferase Inhibitor Entacapone in the Treatment of Parkinson's Disease: Personal Reflections on a First-in-Class Drug Development Programme 40 Years On. methyltransferases, parkinson disease, brain, pharmaceutical preparations, therapeutics, levodopa, catechol o-methyltransferase, drug development, tolcapone | Neurol Ther | 2024 | 2 |
| Repeated Levosimendan Infusions in the Management of Advanced Heart Failure: Review of the Evidence and Meta-analysis of the Effect on Mortality. mortality, heart failure, cardiovascular agents, therapeutics | J Cardiovasc Pharmacol | 2024 | 3 |
Clinical Studies 2
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
LeadR Networks
Main global connection map